Fact checked by Jennifer Klump When Maureen Sideris, 71, was diagnosed with gastroesophageal junction cancer in 2022, doctors ...

Patients with certain types of early stage cancer, particularly those affecting the gastrointestinal system, may be able to ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Belgian clinical-stage biotech iTeos Therapeutics (Nasdaq: ITOS) saw its shar leap18.6% to $8.20 today, despite posting ...

Congress is considering reducing the amount of time that pharmaceutical drugs will be patent protected. Stop and think about ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a ...

This new immunotherapy is particularly effective in several types of solid tumors, but it will take time to confirm its ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...